ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
December 05 2023 - 8:30AM
via NewMediaWire – ABVC BioPharma, Inc. (“ABVC” or the
“Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical
company developing therapeutic solutions in oncology/hematology,
CNS, and ophthalmology, today shared an interview with Dr. Scott
Irwin, MD, Ph.D., an eminent Professor of Psychiatry and Behavioral
Neurosciences at Cedars-Sinai Medical Center (CSMC). Dr. Irwin
serves as the Principal Investigator for the clinical trials of
ABV-1601, the Company’s drug under development to treat depression
in cancer patients.
“Dr. Irwin is trustworthy, sincere, devoted to the work, and
takes things that concern his patients seriously. We are grateful
for him joining our study as the principal investigator,”
said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. He
added that the Company believes Dr. Irwin’s ideas and comments will
aid in completing the trials on a positive note.
Follow the link to hear the full interview with Dr. Irwin and to
learn about why patients are taking lots of medications and looking
for something natural to treat their depression.ABVC BioPharma
Website: https://abvcpharma.com/?page_id=17615Youtube: https://youtu.be/QZ754OpWC7E?si=dews4u1fMpAENWDG
According to Global Market Insights, Antidepressant Drugs Market
size exceeded USD 13.5 billion in 2020 and is anticipated to grow
at over 7.2% CAGR between 2021 and 2027.[1]
About ABVC BioPharmaABVC BioPharma is a clinical-stage
biopharmaceutical company with an active pipeline of six drugs and
one medical device (ABV-1701/Vitargus®) under development. For its
drug products, the Company utilizes in-licensed technology from its
network of world-renowned research institutions to conduct
proof-of-concept trials through Phase II of clinical development.
The Company’s network of research institutions includes Stanford
University, University of California at San Francisco, and
Cedars-Sinai Medical Center. For Vitargus®, the Company intends to
conduct global pivotal clinical trials for PMA (pre-Market
Approval).
Forward-Looking StatementsThis press release contains
“forward-looking statements.” Such statements may be preceded by
the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential,” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions, and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified, and, consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. None of the outcomes
expressed herein are guaranteed. Such risks and uncertainties
include, without limitation, risks and uncertainties associated
with (i) our inability to manufacture our product candidates on a
commercial scale on our own, or in collaboration with third
parties; (ii) difficulties in obtaining financing on commercially
reasonable terms; (iii) changes in the size and nature of our
competition; (iv) loss of one or more key executives or scientists;
and (v) difficulties in securing regulatory approval to proceed to
the next level of the clinical trials or to market our product
candidates. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company
assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events or otherwise.
Contact:Leeds ChowEmail: leedschow@ambrivis.com
[1] https://www.gminsights.com/industry-analysis/antidepressant-drugs-market
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Apr 2023 to Apr 2024